Holen Sie sich die Stockscreener-App
0.1752
3.20%
-0.0058
Handel nachbörslich:
.18
0.0048
+2.74%
Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Bitget
Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView
Theriva Biologics reports $13.1M year-end cash, $25.2M net loss for 2025 - TradingView
Form 10-K Theriva Biologics, Inc. For: Dec 31 - StreetInsider
Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan
Aug Mood: Can Theriva Biologics Inc maintain sales growthStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Shorts: Can Theriva Biologics Inc maintain sales growthAnalyst Upgrade & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Stocktwits
TOVX Should I Buy - Intellectia AI
TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Stocktwits
TOVX Technical Analysis & ETF Price Forecast - Intellectia AI
Is Theriva Biologics Inc. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum - GlobeNewswire Inc.
Aug Update: What are Theriva Biologics Incs technical support levelsJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications - marketscreener.com
Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications - TradingView
Theriva Biologics (TOVX) Licenses SYN-020 to Rasayana Therapeuti - GuruFocus
Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks
Theriva Biologics Inc (referred to as Theriva Biologics) has successfully received a $300,000 upfront payment at the time of signing the agreement. - Bitget
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Bitget
How Theriva Biologics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Daily Price Action Insights - mfd.ru
Published on: 2026-02-14 06:14:36 - mfd.ru
Theriva Biologics Faces Delay in Warrant Approval Meeting - The Globe and Mail
How Theriva Biologics Inc. stock correlates with oil marketsM&A Rumor & Comprehensive Market Scan Insights - mfd.ru
Will Theriva Biologics Inc. outperform its industry peersWeekly Stock Report & Low Drawdown Trading Strategies - mfd.ru
Theriva Biologics Reschedules Stockholder Meeting - TradingView
Theriva Biologics (NYSE: TOVX) to reschedule vote on 16.18M warrant shares - Stock Titan
Death Cross: Can Theriva Biologics Inc. grow without dilutionJuly 2025 Selloffs & Daily Entry Point Trade Alerts - mfd.ru
Published on: 2026-02-09 23:08:24 - mfd.ru
Analyst Downgrade: Why is Theriva Biologics Inc stock going downJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Bond Watch: Is Theriva Biologics Inc. subject to activist investor interest2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data - GlobeNewswire
Trial tests VCN-01 before eye removal in hard-to-treat retinoblastoma - Stock Titan
Street Watch: Is Theriva Biologics Inc showing insider buyingWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Theriva Biologics Inc backed by strong institutional buyingJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell? - Defense World
Dow Update: Can Theriva Biologics Inc continue delivering strong returnsWeekly Trade Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Theriva Biologics Inc continue delivering strong returnsQuarterly Portfolio Summary & Long-Term Growth Plans - baoquankhu1.vn
Theriva Biologics advances VCN-01 toward Phase 3 trial - TipRanks
How Theriva Biologics Inc. stock performs in rate cut cyclesProfit Target & Consistent Growth Equity Picks - Улправда
How Theriva Biologics Inc. stock reacts to fiscal policiesPortfolio Return Summary & AI Forecasted Entry/Exit Points - Улправда
Will Theriva Biologics Inc. stock profit from fiscal stimulusJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - Улправда
Can Theriva Biologics Inc. stock maintain operating margins2025 Trading Recap & Technical Analysis for Trade Confirmation - Улправда
Is Theriva Biologics Inc. stock undervalued vs historical averagesOil Prices & Risk Managed Investment Entry Signals - Улправда
Can Theriva Biologics Inc. stock deliver sustainable ROE2025 Technical Overview & Comprehensive Market Scan Insights - ulpravda.ru
Will Theriva Biologics Inc. stock benefit from green energy trends2026 world cup usa national team semifinals defensive leaders pressing system match prediction preview - ulpravda.ru
Why Theriva Biologics Inc. stock is favored by pension funds2026 world cup usa national team quarterfinals goalkeepers low block defense match prediction statistical analysis - Улправда
How Theriva Biologics Inc. stock benefits from strong dollar2026 world cup usa national team group stage playmakers possession football winner prediction insights - Улправда
Theriva Biologics Incto Schedule End-of-Ph - 富途牛牛
Sentiment Watch: Is Theriva Biologics Inc stock at risk of policy regulationJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - Bộ Nội Vụ
Theriva Biologics receives EMA approval for VCN-01 Phase 3 trial - Intellectia AI
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design - Yahoo Finance
Theriva Biologics gains EMA backing for VCN-01 phase 3 - MSN
Theriva receives EMA guidance for pancreatic cancer drug trial design By Investing.com - Investing.com Nigeria
Why Is Theriva Biologics Stock Gaining Monday? - Benzinga
Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com Nigeria
Theriva Biologics (TOVX) Prepares for Phase 3 Trial with EMA Gui - GuruFocus
Theriva Biologics Announces EMA Advice on Phase 3 Trial for VCN-01 - TradingView — Track All Markets
Theriva Biologics (TOVX) outlines EMA CHMP advice on VCN-01 Phase 3 trial in metastatic pancreatic cancer - Stock Titan
0.48%
1.21%
Kapitalisierung:
|
Volumen (24h):